Al­ny­lam makes a bull case for PhI­II-ready por­phyr­ia drug, but shares sink any­way

Al­ny­lam to­day of­fered some de­tails on the da­ta it has gath­ered from a small, ear­ly-stage study of givosir­an for rare cas­es of por­phyr­ias. The da­ta pro­vide some in­sights on the ther­a­py’s pos­i­tive im­pact in pre­vent­ing fresh at­tacks, but the biotech’s shares $AL­NY were down 3.6% in af­ter­noon trad­ing as an­a­lysts looked through the num­bers and pon­dered the dura­bil­i­ty of a re­cent run-up in the stock price.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.